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ABSTRACT 12 
In nature, bacteria predominantly reside in structured, surface-attached communities embedded 13 
in a self-produced, extracellular matrix. These so-called biofilms play an important role in the 14 
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development and pathogenesis of many infections, as they are difficult to eradicate due to their 15 
resistance to antimicrobials and host defense mechanisms. This review focusses on the biofilm-16 
forming periodontal bacterium Porphyromonas gingivalis. Current knowledge on the virulence 17 
mechanisms underlying P. gingivalis biofilm formation is presented. In addition, oral infectious 18 
diseases in which P. gingivalis plays a key role are described and an overview of conventional 19 
and new therapies for combating P. gingivalis biofilms is given. More insight into this 20 
intriguing pathogen might direct the development of better strategies to combat oral infections. 21 
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1. Introduction  26 
Biofilms are aggregates of microorganisms adherent to each other and/or to a surface and 27 
encapsulated within a self-produced matrix (1). These organized communities represent a 28 
significant health risk due to their resistance to host defense mechanisms and their decreased 29 
susceptibility to conventional antimicrobials (1, 2). Biofilm-mediated resistance has been 30 
attributed to impaired penetration of antimicrobials through the matrix, increased expression of 31 
drug-resistance genes, and reduced metabolic activity of cells residing in the biofilm (3). 32 
Because of their involvement in over 80 % of all bacterial infections in humans, biofilms have 33 
been the subject of intensive research for many years (4).  34 
The oral cavity provides a habitat for approximately 700 microbial species forming complex 35 
and dynamic multispecies biofilms, also referred to as “dental plaque” (5, 6). The oral Gram-36 
negative anaerobic bacteria P. gingivalis is typically a late colonizer of subgingival biofilms 37 
and has been correlated with several destructive periodontal diseases, including periodontitis 38 
and peri-implantitis (7–9). P. gingivalis’ pathogenicity is reflected in an arsenal of virulence 39 
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factors involved in tissue colonization and destruction, and interference with host defense 40 
systems (10, 11).  41 
In this review, an overview of the current knowledge on P. gingivalis biofilm formation is first 42 
presented. Next, biofilm infections in which P. gingivalis plays a key role are described and 43 
finally conventional treatment strategies and new approaches to combat P. gingivalis biofilms 44 
are discussed. 45 
 46 
2. Biofilm formation by P. gingivalis 47 
Biofilm development is a complex, dynamic, multistage process (1). Initially, bacteria adhere 48 
to abiotic or biotic surfaces by production of surface appendages (initial adherence). Next, 49 
biofilms mature by the development of a three-dimensional structure containing microcolonies 50 
in which different species can interact with each other (biofilm maturation). In a last phase, 51 
cells disperse from the biofilm, allowing the formation of new biofilms (biofilm dispersal) (1, 52 
12). Novel strategies to treat P. gingivalis infections benefit from thorough insight in the 53 
virulence mechanisms underlying biofilm formation. However, to date, knowledge on the 54 
molecular basis of biofilm formation by P. gingivalis is largely fragmentary. Approximately 18 55 
% of the P. gingivalis genome is differentially expressed when the bacteria is grown as a 56 
biofilm, demonstrating the complexity of biofilm development (13). Below, we describe the 57 
involvement of surface structures, quorum sensing, heme uptake and nutritional interactions in 58 
in vitro biofilm formation by this pathogen (Fig. 1).  59 
 60 
Role of surface structures in biofilm formation 61 
Given the wide variety of substrates to which P. gingivalis can attach in the oral cavity (e.g. 62 
oral soft tissues, implant materials, and other bacteria), many extracellular structures play a role 63 
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in mediating specific and stable substrate attachment. Examples include fimbriae, LPS, 64 
internalines, and capsules.  65 
Fimbriae are proteinaceous appendages that are anchored to the outer membrane and play a role 66 
in biofilm formation (Fig. 2). P. gingivalis is known to express two types of fimbriae: long 67 
fimbriae which are composed of FimA subunits, and short fimbriae which are composed of 68 
Mfa1 subunits (14). Loss of FimA results in reduced adherence to human gingival fibroblasts 69 
and epithelial cells, demonstrating that FimA fimbriae play a role in the initial attachment of 70 
bacteria to host cells (15, 16). Furthermore, long fimbriae are involved in P. gingivalis auto-71 
aggregation (17, 18) and P. gingivalis co-aggregation with Actinomyces viscosus (19), 72 
Treponema denticola (20), Streptococcus gordonii (21), and Streptococcus oralis (22). Of note, 73 
mutants deficient in gtfA, a putative glycosyltransferase gene (PG0750), are affected in biofilm 74 
development. These mutants lack mature FimA fimbriae but have an unchanged fimA 75 
expression, indicating that sugar transfer is involved in fimbriae development (23).  76 
Little is known on the role of Mfa1 in P. gingivalis biofilm formation. Short fimbriae are 77 
involved in P. gingivalis co-aggregation with S. gordonii (24). On the other hand, Mfa1-78 
deficient mutants were reported to display enhanced auto-aggregation (18). The latter is 79 
contradicted by an earlier report showing that short fimbriae are required for P. gingivalis auto-80 
aggregation (25). Supporting these findings, elevated expression of short fimbriae in a ClpXP-81 
deficient strain results in increased P. gingivalis biofilm formation (26). 82 
Recent studies have illustrated the importance of extracellular arginine in fimbriae-mediated 83 
biofilm formation. P. gingivalis is unable to form microcolonies with Streptococcus cristatus 84 
as a result of a downregulation of fimA expression by streptococcal ArcA, which catalyzes the 85 
hydrolysis of arginine to citrulline (27). Similarly, ArcA from Streptococcus intermedius 86 
represses FimA and Mfa1 production in P. gingivalis (28). Finally, addition of arginine 87 
promotes P. gingivalis biofilm formation (29).  88 
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In addition to fimbriae, surface-associated LPS have been shown to mediate P. gingivalis 89 
biofilm formation. LPS typically consist of three parts: a lipid A moiety that tethers LPS to the 90 
outer membrane, a core oligosaccharide and an O-antigen polysaccharide (30). The absence of 91 
GalE, which is involved in the synthesis of sugar nucleotides in the Leloir pathway, results in 92 
shortened LPS O-antigens and significantly increases P. gingivalis biofilm formation (31).  93 
Furthermore, surface-attached internalines, which are involved in protein-protein interactions, 94 
have been shown to play a role in initial attachment of the bacteria (32). Indeed, inactivation of 95 
the internalin family protein InlJ reduces P. gingivalis monospecies biofilm formation and 96 
enhances mixed-species P. gingivalis - S. gordonii biofilm formation (32).  97 
Last, P. gingivalis is known to produce a capsular polysaccharide which encases the cell 98 
surface, thereby masking surface components such as LPS and surface proteins. Interestingly, 99 
loss of capsule production positively affects biofilm formation of P. gingivalis (33). On the 100 
other hand, it was reported that P. gingivalis capsules mediate co-aggregation between P. 101 
gingivalis and Fusobacterium nucleatum (34).  102 
 103 
Role of quorum sensing in biofilm formation 104 
Quorum sensing is a bacterial communication mechanism in which expression of genes is 105 
coordinated through the accumulation of specific signaling molecules (35). P. gingivalis utilizes 106 
the LuxS/Autoinducer-2 (AI-2) quorum sensing system (36, 37). luxS encodes the AI-2 107 
synthase which cleaves S-ribosylhomocysteine into 4,5-dihydroxy-2,3-pentanedione (DPD). 108 
Subsequently, DPD undergoes spontaneous derivatizations, forming signaling molecule AI-2 109 
(38). This quorum sensing system has been shown to play a role in inter-species communication 110 
of P. gingivalis. More specifically, AI-2 was demonstrated to be necessary for the formation of 111 
P. gingivalis - S. gordonii mixed biofilms, and AI-2 produced by S. gordonii is able to 112 
complement a luxS mutation in P. gingivalis (39). Similarly, the biovolume of Filifactor alocis 113 
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- P. gingivalis mixed-species biofilms was significantly reduced with a P. gingivalis luxS-114 
mutant, indicating a role for AI-2 in the interaction between P. gingivalis and F. alocis (40). In 115 
addition, it was shown that AI-2 from Actinobacillus actinomycetemcomitans is capable to 116 
complement a luxS mutation in P. gingivalis (41). Finally, it was demonstrated that AI-2 from 117 
F. nucleatum induced both P. gingivalis monospecies biofilm formation and F. nucleatum - P. 118 
gingivalis mixed-species biofilm formation (42).  119 
 120 
Role of heme and heme uptake systems in biofilm formation 121 
Iron is an essential growth factor for most bacteria. Unlike many other microorganisms, P. 122 
gingivalis does not produce siderophores to sequester and transport iron. Instead, the bacterium 123 
utilizes specific proteases such as gingipains and surface-associated proteins to acquire iron 124 
from host heme (43).  125 
Proteolytic gingipains Kgp and Rgp play an important role in the acquisition of iron by releasing 126 
heme from hemoglobin (43). In addition, it was found that Kgp suppresses P. gingivalis auto-127 
aggregation and Rgp mediates microcolony formation and restrains the biovolume (18). 128 
Furthermore, gingipains are involved in adherence of P. gingivalis to epithelial cells and in co-129 
aggregation of P. gingivalis with T. denticola, Prevotella intermedia, and S. aureus (44–46). 130 
Surface-expressed hemagglutinins mediate the acquisition of heme through erythrocyte binding 131 
(47). Furthermore, the heme-binding outer-membrane-associated lipoprotein HmuY and its 132 
cognate receptor HmuR are involved in the capture and internalization of heme (48). Deletion 133 
of hmuY or the hemagglutinin gene hagC results in reduced levels of biofilm, suggesting a role 134 
in biofilm formation (49, 50). In addition, the hemin-associated transcriptional regulator Har, 135 
which controls the expression of hmuY and mfa1, was found to be a positive regulator of biofilm 136 
formation (51). This study also demonstrated that heme-limitation per se decreases P. gingivalis 137 
biofilm formation and development (51). 138 
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 139 
Role of nutritional interactions in biofilm formation 140 
Nutritional interactions have been described to play a role in the co-existence of P. gingivalis 141 
and T. denticola. A study revealed that P. gingivalis produces isobutyric acid which enhances 142 
growth of T. denticola, while T. denticola produces succinate that positively affects growth of 143 
P. gingivalis (52). This may explain the finding that P. gingivalis and T. denticola show 144 
enhanced planktonic and biofilm growth when they are cultured together in comparison to 145 
mono-species growth (52, 53).  146 
 147 
3. Treatment of P. gingivalis-related infections 148 
P. gingivalis is one of the most prevalent bacteria in periodontitis, a chronic inflammatory 149 
disease of the oral cavity (8). This disease is characterized by destruction of the supporting 150 
structures of the teeth (i.e. the gingiva, the periodontal ligament, and the alveolar bone) and can 151 
eventually lead to loss of teeth (54). Furthermore, periodontitis has recently been associated 152 
with an increased risk for delivery of premature labor and low-birth-weight infants (55). The 153 
prevalence of periodontitis is high, with the moderate form affecting up to 46 % and the severe 154 
form 8.9 % of the US population (56). Smoking and diabetes are known major risk factors for 155 
periodontitis (57).  156 
P. gingivalis is also recognized as a keystone pathogen in peri-implantitis, a periodontal disease 157 
characterized by inflammation of the hard and soft tissues surrounding dental implants. When 158 
left untreated, peri-implantitis can result in loss of the dental implant (9, 58). Studies have 159 
reported a considerably high prevalence of peri-implantitis, with estimations ranging from 20-160 
56 % of the patients, depending on the time frame under investigation (59, 60) 161 
 162 
Current strategies 163 
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Treatment procedures of P. gingivalis-mediated diseases such as periodontitis and peri-164 
implantitis focus on the eradication of oral pathogens at the site of infection, usually by surface 165 
debridement procedures followed by adjunctive therapies, including the use of antiseptics 166 
or/and antibiotics (61–66).  167 
The antiseptic chlorhexidine has been widely used in dental practice because of its broad-168 
spectrum antimicrobial activity (67). Local application of chlorhexidine can be done in the form 169 
of gels, chips, mouthwashes or films (68–71). Despite its widespread use, some limitations have 170 
been reported, including brown discoloration of the teeth, alteration in taste, supraginigival 171 
calculus formation and, more rarely, oral mucosal erosion and parotid swelling. Additionally, 172 
chlorhexidine is characterized by a bitter taste, contributing to patient non-compliance (72–74). 173 
Several antibiotic classes have also been suggested for the treatment P. gingivalis-related 174 
infections, including tetracyclines (tetracycline hydrochloride, minocycline, doxycycline), 175 
macrolides (erythromycin), lincosamides (clindamycin), ß-lactams (ampicillin, amoxicillin) 176 
and nitroimidazoles (metronidazole) (64, 75–77). These antibiotics can be administered by 177 
either local or systemic routes. Systemically administered antibiotics can penetrate the 178 
periodontal tissues and reach deep periodontal pockets via serum. In this way, antibiotics can 179 
target oral pathogens that are inaccessible for cleaning instruments or locally applied antibiotics 180 
(78). However, this application route requires good patient compliance, can cause side effects, 181 
and can facilitate antibiotic resistance (66, 79–81). Local administration has the advantage that 182 
higher therapeutic concentration of antibiotics can be delivered inside the pocket, avoiding 183 
some of the side effects of systemic administration. 184 
In the last few years, concerns have been raised about the efficacy of the aforementioned 185 
antimicrobials in treatment of oral biofilm-related infections. First, compared to planktonic 186 
cells, P. gingivalis cells residing in biofilms are less susceptible to antimicrobials such as 187 
chlorhexidine, minocycline, metronidazole, amoxicillin, doxycycline, cefuroxime, ampicillin, 188 
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and ofloxacin (82–87). More specifically, biofilms can be up to 500 times less sensitive to 189 
antibiotics (87). Second, several studies have examined the antibiotic susceptibility of 190 
subgingival microflora isolated from patients suffering from periodontitis and peri-implantitis. 191 
This is illustrated by the finding that 74.2 % of patients with periodontitis and 71.7 % of patients 192 
with peri-implantitis harbor pathogens resistant to at least one standard antibiotic (80, 81). A 193 
recent study also reported that 25.49 %, 23.52 %, and 21.56 % of the P. gingivalis strains 194 
isolated from patients with periodontitis are resistant to amoxicillin, clindamycin, and 195 
metronidazole, respectively (88). Similarly, periodontitis isolates of P. gingivalis were 196 
demonstrated to be resistant against penicillin, amoxicillin, erythromycin, azithromycin, 197 
clindamycin and tetracycline (89).  198 
The current data concerning biofilm-mediated resistance in dental practice together with the 199 
emerging global threat of antimicrobial resistance has prompted researchers to search for new 200 
antimicrobial agents targeting oral pathogens. Newly identified antibacterial agents that show 201 
activity against P. gingivalis biofilms are discussed below.  202 
 203 
New antibacterial agents 204 
Quorum sensing inhibitors 205 
Quorum sensing inhibitors have been presented as promising alternatives for the treatment of 206 
biofilm-related infections as they do not affect growth and thus have a low potential for 207 
resistance development (90). In this respect, quorum sensing inhibitors (5Z)-4-bromo-5-208 
(bromomethylene)-2(5H)-furanone (2 mM) and D-ribose (50 mM) have been shown to reduce 209 
both P. gingivalis monospecies and F. nucleatum and P. gingivalis mixed-species biofilm 210 
development (42). Furthermore, these agents are not toxic for human monocytic cells and 211 
human gingival fibroblasts at tested concentrations, and do not stimulate production of 212 
proinflammatory factors. In addition, these inhibitors remain active against P. gingivalis under 213 
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in vivo conditions, making them suitable candidates for further development into anti-P. 214 
gingivalis drugs (91). 215 
 216 
Antimicrobial peptides 217 
Antimicrobial peptides are widely proposed as a new source of future antibiotics, as they often 218 
have broad spectrum activity and a low tendency for resistance development (92). An overview 219 
of the currently known antimicrobial peptides that show antibiofilm activity against P. 220 
gingivalis is given in Table 1. 221 
 222 
Table 1: Overview of antimicrobial peptides effective against P. gingivalis biofilm formation 223 
Antimicrobial peptide Active concentration Reference 
Cathelicidin-related antimicrobial 
peptide (CRAMP) 
20.3 µM (93) 
Lactoferrin derivatives 8 µg/ml (94) 
Nal-P-113 6.25 µg/ml (95) 
Pac-525 0.5 µg/ml (96) 
BAR 1.3 μM (97) 
 224 
The shortened alanine-substituted peptide AS10, derived from the cathelicidin-related 225 
antimicrobial peptide (CRAMP), which was identified in the islets of Langerhans of the murine 226 
pancreas, was reported to inhibit P. gingivalis biofilm formation (93). Agents derived from 227 
lactoferrin, an iron-binding host defense antimicrobial protein present in saliva and gingival 228 
crevicular fluids, also exhibit antibiofilm activity against P. gingivalis (94). In addition, Nal-P-229 
113, which is a β-naphthylalanine-substituted derivative of the saliva protein histatin 5, has an 230 
effect on P. gingivalis biofilm formation under both in vitro and in vivo conditions, without 231 
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significant cytotoxicity (95). Furthermore, a recent study demonstrated that the newly designed 232 
peptide Pac-525 has the ability to kill bacteria within P. gingivalis biofilms formed on titanium 233 
surfaces at a concentration which does not exert cytotoxic effects against eukaryotic cells (96). 234 
The adhesion of P. gingivalis to primary colonizing bacteria such as S. gordonii has been 235 
recognized as an important step in the initial formation of subgingival biofilms. P. gingivalis is 236 
known to adhere to S. gordonii through interaction of the short fimbrial antigen Mfa1 with a 237 
specific region of the streptococcal SspB polypeptide (designated BAR). In this regard, a recent 238 
study has designed the BAR peptide, a synthetic peptide comprising the BAR sequence, which 239 
has been reported to inhibit adherence of P. gingivalis to S. gordonii, thereby preventing the 240 
formation of P. gingivalis-associated biofilms (97). 241 
 242 
Natural sources 243 
Plant-derived antibacterial agents 244 
To overcome the alarming scarcity of new antibiotic classes, several recent studies have focused 245 
on finding new antibiotics from unexplored natural sources (98). In this context, plants have 246 
proved to be a good new source for finding new antibacterial agents. This is not surprising, as 247 
plants are frequently exposed to bacterial infections and thus have developed various defense 248 
mechanisms to combat bacterial pathogens. Table 2 gives an overview of new antibiotics 249 
derived from plants that affect P. gingivalis biofilm formation.  250 
 251 
Table 2: Overview of plant-derived compounds effective against P. gingivalis biofilm 252 
formation 253 
Plant-derived compound Origin Active concentration  Reference 
Non-dialysable material 
from cranberrry juice 
Vaccinium macrocarpon 62.5 µg/ml (99) 
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A-type cranberry 
proanthocyanidins 
Vaccinium macrocarpon 50 µg/ml (100) 
Prenylated flavonoids Epimedium species 1.25 µM (101) 
Lacinartin Citrus fruits 50 µg/ml (102) 
    
Tea catechin 
epigallocatechin gallate 
Camellia sinensis (tea plant) 10 µg/ml (103) 
Essential oils Medicinal and aromatic 
plants (Aloysia gratissima, 
Coriandrum sativum L., 
Muhlenbergia glomerata, 
Cyperus articulatus, Lippia 
sidoides) 
0.125-1 mg/ml (104) 
Essential oil Shiitake mushroom 
(Lentinula edodes) 
0.97 µg/ml (105) 
Carvacrol Thymus vulgaris, Carum 
copticum and oreganum 
species 
1 % (106) 
Roselle calyx extract Hibiscus sabdariffa L. 0.9 mg/ml (107) 
Capsaicin Capsicum plants (chili 
peppers) 
32 µg/ml (108) 
 254 
 The non-dialyzable material fraction of cranberry juice rich in proanthocyanidins and A-type 255 
cranberry proanthocyanidins extracted from cranberry juice concentrate were shown to exhibit 256 
activity against P. gingivalis biofilms (99, 100). The latter fraction was also found to negatively 257 
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affect adherence to oral epithelial cells and have anti-inflammatory activities by inhibiting the 258 
secretion of interleukin-8 and chemokine ligand 5 (100). Of note, the activity of these A-type 259 
cranberry proanthocyanidin can be increased by combination therapy with Licochalcone A, a 260 
major chalcone in licorice root (109).  261 
A number of prenylated flavonoids isolated from Epimedium species were reported to inhibit 262 
biofilm formation by P. gingivalis and to interfere with Rgp and Kgp gingipain activity (101).  263 
Lacinartin derived from Citrus fruits and Tea catechin derived from Camellia sinensis have 264 
been demonstrated to inhibit biofilm formation of P. gingivalis biofilms and to desorb pre-265 
formed biofilms (102, 103). Furthermore, Lacinartin negatively affected adherence to epithelial 266 
cells.  267 
Extracted oils obtained from plants also possess activity against P. gingivalis biofilms. Indeed, 268 
essential oils extracted from medicinal and aromatic plants such as Aloysia gratissima, 269 
Coriandrum sativum L., Muhlenbergia glomerata, Cyperus articulatus, Lippia sidoides and 270 
from shiitake have been reported to inhibit P. gingivalis biofilm formation (104, 105). 271 
Additionally, carvacrol, a monoterpene phenol present in the volatile oils of Thymus vulgaris, 272 
Carum copticum and oreganum species, inhibits P. ginigvalis biofilm formation on titanium 273 
implant material (106). 274 
Recent studies revealed the antibiofilm effects of roselle calyx extract and capsaicin, which is 275 
the active compound of Capsicum plants (chili peppers) against P. gingivalis (107, 108). The 276 
latter also reduces the viability of pre-formed biofilms and has an inhibitory effects on both 277 
inflammatory cytokine secretion and in vitro osteoclastogenesis. 278 
 279 
Saccharides of marine origin 280 
In recent years, the marine environment has been explored as a source for finding new natural 281 
antibacterial agents. In this context, OligoG, which is an oligosaccharide derived from brown 282 
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algae alginate, was found to drastically reduce biofilm formation of P. gingivalis (110). 283 
Furthermore, treatment of titanium surfaces with triclosan combined with OligoG significantly 284 
decreases P. gingivalis attachment to titanium surfaces compared to treatment of the surfaces 285 
with triclosan alone. 286 
Chitosan, which is a natural linear polysaccharide derived from chitin present in the exoskeleton 287 
of marine crustaceans, has also been reported to have antibiofilm activities against P. gingivalis 288 
(111).  289 
 290 
Sugar alcohols 291 
Sugar alcohols are commonly used in place of sucrose as non-cariogenic sweeteners. However, 292 
little is known about their activity against periodontal bacteria (112). A recent study reported 293 
that the sugar alcohol erythritol effectively inhibits P. gingivalis biofilm formation and reduces 294 
P. gingivalis accumulation onto S. gordonii substrata (113). The authors concluded that 295 
erythritol acts via several pathways, including suppression of growth resulting from DNA and 296 
RNA depletion, attenuated extracellular matrix production, and alterations of dipeptide 297 
acquisition and amino acid metabolism. 298 
 299 
Other compounds 300 
Screening of compound libraries has resulted in the identification of new antibacterial agents 301 
that show activity against P. gingivalis. We screened a compound library in search for new 302 
molecules that exhibit activity against the opportunistic pathogen Pseudomonas aeruginosa 303 
(114). From this screening, a dichlorocarbazol derivative was identified as a new antibacterial 304 
agent with broad-spectrum activity, including activity against P. gingivalis biofilms. In another 305 
study a library of small molecules based on 2-aminoimidazole and 2-aminobenzimidazole 306 
scaffolds was screened with the aim of identifying compounds that could inhibit co-colonization 307 
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of P. gingivalis and S. gordonii. In this screening, three small molecules derived from oroidin 308 
and containing 2-aminoimidazole or 2 aminobenzimidazole moieties were identified. These 309 
compounds inhibit co-colonization by reducing expression of both mfa1 and fimA fimbrial 310 
genes in P. gingivalis (115). 311 
Drug repurposing has increasingly been applied over the last years as a strategy to uncover new 312 
antibiotics. This strategy has some advantages over de novo drug discovery, including known 313 
toxicological and pharmacological profiles, thereby accelerating the drug development process 314 
significantly (116). In this context, we recently screened a drug-repositioning library (NIH 315 
Clinical Collection) to identify new compounds that show activity against P. gingivalis (117). 316 
The screen led to the discovery of three new molecules that show antibiofilm activity against 317 
P. gingivalis: zafirlukast, an anti-asthmatic drug, toremifene, an anti-cancer drug, and N-(4-318 
Hydroxyphenyl)arachidonylamide (AM404), an active metabolite of paracetamol (117–119). 319 
The anthelmintic drug oxantel, which is typically used for treatment of intestinal worms, has 320 
also been proven to significantly inhibit biofilm formation by P. gingivalis by inhibition of 321 
fumarate reductase. Furthermore, oxantel is more effective than the conventional antibiotic 322 
metronidazole in inhibiting P. gingivalis biofilms (120). In a follow-up study, it was 323 
demonstrated that oxantel can disrupt the development of polymicrobial biofilms composed of 324 
P. gingivalis, Tannerella forsythia, and T. denticola in a concentration-dependent manner 325 
(121).  326 
 327 
Antibacterial coatings 328 
Coating of titanium surfaces with antibacterial agents has recently been explored as a new 329 
strategy for the prevention of peri-implant infections (122). A number of studies have 330 
investigated the potential of antibacterial peptides to be used in coating applications. Indeed, 331 
coatings that are functionalized with GL13K (derived from the human salivary protein Parotid 332 
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Secretory Protein (BPIFA2)), histatin-5 (belonging to a family of peptides secreted by the major 333 
salivary glands), lactoferricin (generated by gastric pepsin cleavage of lactoferrins), and 334 
synthetic peptide Tet213 have been demonstrated to strongly reduce P. gingivalis biofilm 335 
formation (123–125).  336 
The antibiofilm activity of titanium surfaces coated with silver has also been explored. As such, 337 
titanium surfaces coated with silver-hydroxyapatite/titania nanocomposites have been shown 338 
to act both bactericidal and antiadhesive against P. gingivalis (126). In addition, the potential 339 
of silver- and gallium-doped phosphate-based glasses to inhibit growth of P. gingivalis - S. 340 
gordonii dual-species biofilms has been demonstrated (127). Furthermore, a follow-up study 341 
showed that the gallium-doped phosphate-based glasses remain active against P. gingivalis 342 
under in vivo conditions (128). 343 
Also bifunctional coatings with both antibacterial and pro-osteodifferentiation capabilities have 344 
been developed. Simvastatin is known to increase the osteogenic capability of mesenchymal 345 
stem cells while metronidazole is an antimicrobial agent that has excellent activity against strict 346 
anaerobic bacteria. Integration of these drugs into a calcium phosphate coating for titanium 347 
surfaces prevents the growth of P. gingivalis and increases osteogenic cell differentiation (129).  348 
 349 
4. Concluding remarks  350 
P. gingivalis is a notorious pathogen in the development of periodontitis and peri-implantitis. 351 
As these infections are biofilm-related, conventional antimicrobials often fail to eradicate the 352 
entire biofilm, which results in chronic infections and necessitates surgical removal of infected 353 
areas. Thus, there exists a need for the development of new antibacterials to combat biofilm-354 
related infections.  355 
In recent years, a significant number of new compounds with antibiofilm activity against P. 356 
gingivalis have been identified. Unfortunately, to our knowledge, only one compound has 357 
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progressed to clinical trials: the antibacterial peptide lactoferrin (94). Different factors may 358 
explain the limited availability of new antibacterial drugs. For example, in spite of the 359 
promising results of the above-mentioned antibacterial peptides, there are still some challenges 360 
to their applications, such as potential toxicity, susceptibility to proteases, and high production 361 
costs (130). As for the natural products interfering with P. gingivalis biofilm formation, limited 362 
information is currently present on their mode of action and their cytotoxicity. In addition, the 363 
active concentrations of some plant-derived compounds are up to 1000 times higher than 364 
conventional antibiotics, indicating limited antibacterial activity (83, 84, 87). Regarding the 365 
surface coating strategies to prevent biofilm formation on implants, there still exists a great 366 
discrepancy between the suggested strategies and their clinical applications (131). Furthermore, 367 
potential limitations of these coatings such as toxicity and hampered antibacterial activity under 368 
in vivo conditions should be tackled in future studies (131, 132). 369 
Thus, further mode of action studies, comprehensive toxicity analyses and in vivo tests will be 370 
necessary to fully reveal the potential of newly discovered antibacterial agents to be used in the 371 
treatment of oral infections. In addition, a broader knowledge of the regulatory and molecular 372 
mechanisms behind P. gingivalis biofilm formation may further accelerate the development of 373 
future strategies for treatment of P. gingivalis-associated infections.  374 
 375 
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FIGURES 734 
 735 
Fig. 1. Determinants involved in biofilm formation by P. gingivalis. A schematic 736 
representation of the involvement of surface structures (fimbriae, LPS, internalines, and 737 
capsules), quorum sensing (LuxS/AI-2), and heme uptake (gingipains, hemagglutinins and 738 
HmuY/HmuR) in in vitro biofilm formation. 739 
 740 
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 741 
Fig. 2. Overview of interactions of P. gingivalis fimbriae FimA and Mfa1 with epithelial cells 742 
and other bacteria. A question mark indicates a hitherto unclear effect or interaction. 743 
 744 
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